Ivacaftor | Page 3 | European Cystic Fibrosis Society (ECFS)

A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutati

Azithromycin and Tezacaftor/Ivacaftor is associated with first-degree heart block in an adult with Cystic Fibrosis

Clinical effects of the three CFTR potentiator treatments curcumin, genistein and ivacaftor in patients with the CFTR-S1251N gating mutation

Lumacaftor/ivacaftor reduces exacerbations in adults homozygous for Phe508del mutation with severe lung disease

Accumulation and persistence of Ivacaftor in airway epithelia with prolonged treatment

Ivacaftor in Cystic Fibrosis With Residual Function: Lung Function Results From an N-of-1 Study

GLPG2737 in lumacaftor/ivacaftor-treated CF subjects homozygous for the F508del mutation: A randomized phase 2A trial (PELICAN).

CFTR activity is enhanced by the novel corrector GLPG2222, given with and without ivacaftor in two randomized trials

Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis.

Use is Associated with Higher Hemoglobin Levels in Individuals with Cystic Fibrosis

first
previous
1
2
3
4
5
next
last